home

KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite sublingual allergy immunotherapy (SLIT) tablet. The BLA for Merck's investigational house dust mite SLIT-tablet is supported by a comprehensive clinical program involving more than 4,000 patients, including two Phase III in-field trials that ev

Trendmerck2016-04-14 09:48 Read   72

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite sublingual allergy immunotherapy (SLIT) tablet.

Facebook, Napster pioneer Sean Parker sets up $250M immuno-oncology center

EVENTSfiercebiotech2016-04-14 09:42 Read   47

The billionaire Silicon Valley veteran Sean Parker will inject $250 million into the immuno-oncology research field in an effort to boost cancer survival rates.

Baylor scientists ID dendritic cells as new cancer therapy targets

R&Dfiercebiotech2016-04-14 09:33 Read   63

 One of the ways cancer cells are effective at suppressing the host immune response is by turning off a surface protein called CTLA-4.

C-Myc oncogene determines function of immune cells

R&Dfiercebiotech2016-04-14 09:07 Read   90

Asymmetric cell division plays an important role during the development of our nervous and digestive systems. It is thought that T cells, a type of immune cell, can also divide asymmetrically, giving rise to two different daughter cells.

SynteractHCR CRO 'looking for a $1.5B sale'

EVENTSfiercebiotech2016-04-14 09:03 Read   98

Privately-owned SynteractHCR is seeking a sale of its business and values itself at around $1.5 billion as its investor group owner looks to cash in on the major boon in the CRO sector.

AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease

Trendastrazeneca2016-04-14 08:53 Read   188

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.  

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

EVENTSglobenewswire2016-04-13 17:29 Read   69

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the Japan Patent Office has granted the Company two key patents addressing

Autoimmune Disease Diagnostics Market To Grow At 2.6% CAGR From 2014 to 2020: Grand View Research, Inc.

EVENTSglobenewswire2016-04-13 17:19 Read   115

According to the new report published by Grand View research, the global Autoimmune disease diagnostics market size will reach $ 5.74 Billion By 2020,growing at CAGR of 1.9 %, rising cases of autoimmune disease and the significant increase in healthcare expenditure have accelerated the launch of favorable government initiatives to encourage diagnostics and research organizations

First UK cancer patient scanned with 'revolutionary' imaging technique

Healthpharmatimes2016-04-13 17:05 Read   62

The first patient cancer patient in Europe has been scanned with a revolutionary imaging technique being trialled in the UK that could enable doctors to determine whether a drug is working within days of starting treatment.

SMC accepts three new drugs for NHS use, but bans two

EVENTSpharmatimes2016-04-13 16:58 Read   84

Three new medicines have been cleared for use by NHS Scotland by cost regulator the Scottish Medicines Consortium (SMC), bringing patients new options for breast cancer, fungal infection and warts.

National supply chain for med devices to save NHS millions

EVENTSpharmatimes2016-04-13 16:51 Read   96

NHS England has unveiled a new nationwide system for purchasing expensive medical devices which, it claims, could save the NHS over £60 million in its first two years, partly through reducing variation in cost.

Rite Aid opened 23 clinics in 2015, earned $30 billion as Walgreens takeover nears

EVENTShealthcarefinancenews2016-04-13 16:44 Read   69

Rite Aid earned nearly $166 million and opened 23 health clinics in 2015, the company announced in what may be its last full-year earnings report before its scheduled takeover by Walgreens.